Registered clinical trials of MSCs in COVID-19. In this table, a number of representable clinical trials are summarized. Data were considered as defined in the www.clinicaltrials.gov. Intravenous infusion of MSCs was performed in the listed clinical trials
| NCT number | Title | Status | Phase | No of patients | MSCs origin | No of MSCs |
|---|---|---|---|---|---|---|
| NCT04444271 | Mesenchymal Stem Cell Infusion for COVID-19 Infection | Recruiting | II | 10 | Frozen MSCs | 2 × 106 cells/kg |
| NCT04713878 | Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia | Completed | N/A | 21 | Undefined | Undefined |
| NCT04565665 | Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome | Recruiting | I | 70 | UCB-MSCs | Undefined |
| NCT04416139 | Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19 | Recruiting | II | 10 | Allogeneic-MSCs | 1 × 106 cells/kg |
| NCT04252118 | Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19 | Recruiting | I | 20 | Undefined | 3 times of 3 × 107 cells |
| NCT04313322 | Treatment of COVID-19 Patients Using Wharton’s Jelly-Mesenchymal Stem Cells | Recruiting | I | 5 | WJ-MSCs | Undefined |
| NCT04336254 | Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients | Recruiting | I/II | 20 | Allogeneic Dental Pulp MSCs | 3 × 107 cells |
| NCT04611256 | Mesenchymal Stem Cells in Patients Diagnosed With COVID-19 | Recruiting | I | 20 | AT-MSCs | 1 × 106 cells/kg |
| NCT04346368 | Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease-19 (COVID-19) | Not Yet Recruiting | I/II | 20 | BM-MSCs | 1 × 106 cells/kg |
| NCT04366271 | Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19 | Recruiting | II | 106 | Allogeneic UC-MSCs | Undefined |